Evolus, Inc. (LON:0K16)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 556.56M |
| Revenue (ttm) | 212.69M |
| Net Income (ttm) | -40.27M |
| Shares Out | n/a |
| EPS (ttm) | -0.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52 |
| Average Volume | 3,893 |
| Open | 14.31 |
| Previous Close | 14.16 |
| Day's Range | 14.31 - 14.58 |
| 52-Week Range | 7.12 - 15.38 |
| Beta | n/a |
| RSI | 65.90 |
| Earnings Date | May 9, 2025 |
About Evolus
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California. [Read more]
Financial Performance
In 2024, Evolus's revenue was $266.27 million, an increase of 31.76% compared to the previous year's $202.09 million. Losses were -$50.42 million, -18.26% less than in 2023.
Financial numbers in USD Financial StatementsNews
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team w...
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763...
Evolus, Inc. 2024 Q4 - Results - Earnings Call Presentation
The following slide deck was published by Evolus, Inc.
Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript
Evolus Inc Reports Q4 2024 Revenue of $79 Million, Surpassing Estimates; EPS Misses at -$0.11
Evolus Inc Reports Q4 2024 Revenue of $79 Million, Surpassing Estimates; EPS Misses at -$0.11
Evolus posts quarterly profit on strong sales of cosmetic injection
Cosmetic drugmaker Evolus reported a fourth-quarter profit versus a year-ago loss on Tuesday, on strong demand for its wrinkle treatment Jeuveau which competes with Botox.
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results for the fourth ...
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team w...
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team w...
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...
Evolus wins approval for hyaluronic acid dermal fillers
US FDA approves Evolus' anti-wrinkle gels
Evolus said on Thursday the U.S. Food and Drug Administration has approved its two new anti-wrinkle injectable gels, expanding the company's product portfolio beyond its cosmetic injection Jeuveau.
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administr...
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qu...
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Tuesday. The Dow traded up 1% to 43,920.68 while the NASDAQ rose 0.55% to 19,738.47. The S&P...
Crude Oil Down 2%; D.R. Horton Earnings Top Views
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 450 points on Tuesday. The Dow traded up 1.07% to 43,951.84 while the NASDAQ rose 0.71% to 19,770.38. The S&P 50...
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
Shares of Evolus made a doubly bullish move Tuesday on a strong preliminary fourth-quarter report and guidance for 2025.
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday
Full story available on Benzinga.com
Evolus announces Q4 preliminary unaudited net revenue of $79M
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net...
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in Januar...
Evolus: Still Bullish, But Business Faces Tricky Challenges In '25
Evolus Inc (EOLS) Shares Gap Down to $10.33 on Jan 8
Evolus Inc (EOLS) Shares Gap Down to $10.33 on Jan 8
Evolus Inc (EOLS) Trading Down 3.61% on Dec 27
Evolus Inc (EOLS) Trading Down 3.61% on Dec 27
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in Novemb...